ValuEngine Upgrades Alimera Sciences, Inc. (ALIM) to “Hold”
ValuEngine upgraded shares of Alimera Sciences, Inc. (NASDAQ:ALIM) from a sell rating to a hold rating in a research note issued to investors on Thursday, July 13th.
Several other analysts also recently issued reports on ALIM. HC Wainwright set a $5.00 price target on shares of Alimera Sciences and gave the company a buy rating in a report on Tuesday, July 11th. Zacks Investment Research raised shares of Alimera Sciences from a sell rating to a hold rating in a research note on Thursday, March 30th. Cowen and Company reissued a buy rating and set a $3.00 price objective on shares of Alimera Sciences in a research note on Tuesday, July 11th. Finally, Rodman & Renshaw assumed coverage on shares of Alimera Sciences in a research note on Thursday, April 27th. They set a buy rating and a $4.00 price objective on the stock. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. Alimera Sciences has an average rating of Hold and a consensus price target of $3.38.
Alimera Sciences (NASDAQ:ALIM) opened at 1.53 on Thursday. The company’s 50-day moving average price is $1.43 and its 200 day moving average price is $1.39. The stock’s market capitalization is $99.30 million. Alimera Sciences has a 52-week low of $1.03 and a 52-week high of $1.87.
Alimera Sciences (NASDAQ:ALIM) last announced its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.01. The business had revenue of $10.40 million during the quarter, compared to analysts’ expectations of $10.20 million. During the same period last year, the company earned ($0.17) EPS. The firm’s revenue for the quarter was up 8.3% on a year-over-year basis. On average, equities research analysts predict that Alimera Sciences will post ($0.21) earnings per share for the current fiscal year.
A number of institutional investors have recently modified their holdings of the company. KCG Holdings Inc. raised its position in shares of Alimera Sciences by 127.0% in the first quarter. KCG Holdings Inc. now owns 78,604 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 43,977 shares during the period. JW Asset Management LLC raised its position in shares of Alimera Sciences by 15.6% in the second quarter. JW Asset Management LLC now owns 966,000 shares of the biopharmaceutical company’s stock valued at $1,343,000 after buying an additional 130,000 shares during the period. Finally, Kennedy Capital Management Inc. acquired a new stake in Alimera Sciences during the first quarter valued at about $467,000. 43.58% of the stock is owned by hedge funds and other institutional investors.
Alimera Sciences Company Profile
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Stock Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related stocks with our FREE daily email newsletter.